ONE-WAYOngoing theme · still written in the latest filings
Approval, NHI drug price listing and commercial launch of the regenerative cell therapy SB623
A commercialization initiative for the proprietary regenerative cell therapy SB623 (Acugo®), progressing from regulatory approval and inclusion in the NHI drug price list through shipment preparations to commercial launch.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.